C-2-90

C-2-90 is a preclinical-stage allogeneic (universal) chimeric antigen receptor (CAR) cell therapy being developed by Chongqing Precision Biotech Co., Ltd. The product is built upon the company's proprietary **LstCAR** (Long-term survival CAR) platform, which is designed to create "off-the-shelf" cell therapies that can be administered to multiple patients without the need for patient-specific manufacturing. While the specific antigenic target and primary disease indications have not been publicly disclosed, the LstCAR platform generally aims to overcome the limitations of autologous CAR-T therapies, such as high cost and manufacturing time, by utilizing cells from healthy donors. The program is currently in the preclinical phase of development.